Sensorion appoints Fred Chereau CEO as Audiogene trial data show six-month durability
May 19, 2026
Sensorion appointed Fred Chereau chief executive effective June 1, 2026, while reporting six-month Audiogene trial data for SENS-501. The company said early hearing improvements in cohort 2 persisted at six months and no serious adverse events were reported.